Clinical Briefings™: Assessing and Managing Ocular Health in Glaucoma

Released On
January 29, 2020

Expires On
January 29, 2021

Media Type

Completion Time
60 minutes

Ophthalmology, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


Supported by an educational grant from Allergan.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward ophthalmologists and other healthcare professionals who are involved in glaucoma and ocular health.

Program Overview

As a leading cause of blindness, glaucoma requires critical diagnostic and treatment skills among ophthalmologists and other eye care professionals. Topical agents with a variety of mechanisms of action are available for lowering intraocular pressure (IOP), as are procedures, and choosing the appropriate option for each patient can be challenging. Emerging data on potential harms from the topical preservative benzalkonium chloride (BAK) can make treatment selection more complex for some patients. This program provides an overview of the glaucoma treatment landscape, including IOP target goals; surgical and medical options, including preservative-free choices; and emerging therapies. Accompanying audio from a glaucoma expert provides additional detail and clinical perspective.

Benefits of Participating

This activity will better prepare you to:

  • Weigh factors in setting treatment goals for patients with glaucoma
  • Compare and contrast the benefits and risks of currently available glaucoma treatments, including preservative-free topical medications
  • Track the development of emerging glaucoma therapies

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Characterize current intraocular agents used to treat glaucoma according to efficacy, safety, and preservative content
  • Describe the common effects of long-term BAK on the conjunctiva, cornea, lens, and trabecular meshwork
  • Evaluate the efficacy and safety of alternative preservatives and preservative-free formulations for the management of intraocular pressure


Oluwatosin U. Smith, MD

Attending Physician
Glaucoma Associates of Texas
Clinical Associate Professor
Department of Ophthalmology
University of Texas South Western
Dallas, TX

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Oluwatosin U. Smith, MD

  • Grant/Research Support: Allergan, Santen, American Glaucoma Society
  • Consultant: Aerie Pharmaceuticals, Allergan, Gore, Index, New World Medical, Glaukos Corporation
  • Speaker’s Bureau: Allergan, Aerie Pharmaceuticals, Bausch & Lomb.

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.